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Hyperglycemia has been associated with increased morbidity and mortality in hospitalized patients. Insulin has
traditionally been the drug of choice for managing hyperglycemia in this setting, but carries a significant risk of
hypoglycemia. Incretin-based therapies, including glucagon-like peptide-1, glucagon-like peptide-1 receptor
agonists and dipeptidyl peptidase-4 inhibitors, have potential use in the hospital. These agents have a relatively
low risk of hypoglycemia, favorable short-term side effect profile, and can be used alone or in combination
with insulin. Several small studies have supported the safety and efficacy of incretin therapies in the inpatient
setting with the majority of data coming from the intensive care setting. Large-scale clinical studies are needed
to further evaluate the potential role of incretins in the management of inpatient hyperglycemia.
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Hyperglycemia in the inpatient setting is commonly en-
countered in patients with and without known diabetes.
While patients with diabetes account for an estimated 25-
30 % of adult admissions, a significant percentage of hos-
pitalized hyperglycemic patients have either unrecognized
diabetes or stress hyperglycemia [1–3]. Hyperglycemia is
now a well-established predictor of morbidity and mortal-
ity in patients with both diabetes and stress hyperglycemia
[4]. Several randomized controlled trials evaluating tight
glucose control (BG goal of 80–110 mg/dl) in the hospital
have had conflicting outcomes, therefore treatment targets
of blood glucose are more liberal now (140–180 mg/dl0)
[5]. Tight glucose targets may be beneficial in select pa-
tient populations such as post-operative, steroid-induced,
or trauma-related hyperglycemia [6, 7], but this is limited
by hypoglycemia, which is also a known predictor of poor
outcomes [7, 8]. Given the increasing prevalence of
hyperglycemia in the hospital, there is great interest in
providing effective glycemic management while avoiding
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creativecommons.org/publicdomain/zero/1.0/A wealth of clinical experience using insulin in the in-
patient setting exists, where it remains the preferred
method of glycemic control [5, 9]. Insulin given intraven-
ously has several advantages including a short half-life and
the ability to be rapidly titrated. However, insulin therapy is
labor intensive and requires extensive training both for
intravenous and subcutaneous use. Additionally, meal dos-
ing is challenging in the hospital and needs to be timed ap-
propriately with food and titrated to the percentage of meal
consumed. Hypoglycemia remains a common problem with
insulin and has an estimated prevalence of 12 % even in
academic medical centers [10]. Insulin has been identified
as one of the most common causes of preventable adverse
drug reactions [11, 12]. Although insulin therapy has been
shown to improve select outcomes [6], it fails to consist-
ently reduce mortality in hospitalized hyperglycemic pa-
tients [13]. Given these drawbacks, identification of other
glucose lowering agents that are safe, effective, and less
labor intensive than insulin would be of great clinical utility
in the inpatient setting.
Among the hypoglycemic agents introduced within the
last decade, incretins have shown the most promise for in-
patient use. They carry a low risk of hypoglycemia, which is
particularly important in the inpatient setting where
changes in oral intake, insulin timing, and comorbid condi-
tions such as acute kidney injury can put patients at riskss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Macdonald et al. Clinical Diabetes and Endocrinology  (2015) 1:4 Page 2 of 6[14]. Additionally these drugs are already well established in
the outpatient setting [15, 16]. Here we review the data for
the use of incretin-based therapies both in the intensive
care unit (ICU) and general ward settings.
Review
Physiology of incretins
The incretin effect is the observation that an enteral glu-
cose load raises insulin levels more than an equivalent
intravenous glucose load [17]. The 2 major incretins in
the human body are glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
[18], which are released in response to glucose and fat
ingestion by the K-cells and L-cells of the intestines re-
spectively [18, 19]. Incretins have wide ranging meta-
bolic effects which include increased insulin secretion
from pancreatic beta cells, decreased glucagon secretion,
decreased glucose production in the liver, increased glu-
cose uptake in the muscle, slowed gastric emptying, and
decreased appetite [18–20]. The suppression of glucagon
by GLP-1 declines towards normoglycemia, as does its
effect on insulin secretion; together these mechanisms
prevent hypoglycemia. Incretins may also have a benefi-
cial impact on beta cell mass and function, possibly de-
creasing the rate of beta cell apoptosis [21, 22]. GLP-1
and GIP are rapidly degraded by the enzyme dipeptidyl
peptidase-4 (DPP-4), accounting for their short half-life
in vivo.
Patients with type 2 diabetes have a blunted incretin
response that can be overcome by supraphysiologic
levels of GLP-1 but not GIP [23–25]. This has led to the
discovery of the incretin mimetic peptide group: GLP-1
receptor agonists (GLP-1RAs) that act on the GLP-1 re-
ceptor but are resistant to degradation by DPP-4 [20].
They are administered subcutaneously and are available
in shorter-acting daily or longer-acting weekly formula-
tions. Longer-acting GLP-1RAs have a greater impact on
fasting glucose, while shorter-acting GLP-1RAs have a
greater effect on post-prandial glucoses [26]. GLP-1RAs
approved for use in the United States include exenatide,
liraglutide, and albiglutide [27]. DPP-4 inhibitors, also
known as incretin enhancers, are oral medications that
act by competitively and reversibly binding the active
site of DPP-4 preventing the breakdown of endogenous
GLP-1 and GIP [28]. There are several DPP-4 inhibitors
currently on the market including sitagliptin, saxagliptin,
linagliptin, and alogliptin [27].
Considerations for use in the inpatient setting
Incretin-based therapies would be desirable in the inpatient
setting for several reasons. Due to their glucose dependent
actions, they carry a low risk of hypoglycemia, especially
when used as monotherapy. By augmenting glucose-
dependent insulin secretion and inhibiting glucagonsecretion these medications also target the underlying
pathophysiology found in patients with stress-induced
hyperglycemia [13]. Dose reduction may be required for pa-
tients with renal insufficiency, but otherwise they require
very little titration. Pharmacokinetics vary between the dif-
ferent agents, but in general the effect on glucose lowering
can be seen relatively quickly, on the order of hours to days
[28–30]. Finally, incretin-based therapies can be used in
combination with insulin to provide further flexibility for
blood glucose lowering than what can be obtained by incre-
tins alone. These properties combined with a favorable
short-term side effect profile make incretins attractive alter-
natives or adjuncts to insulin in the inpatient setting.
The most frequent reported side effects of GLP-1 and
GLP-1RAs in the inpatient setting are gastrointestinal,
including nausea, and vomiting [31]. These side effects
could be particularly important with the initiation of
therapy in the inpatient setting because they tend to be
more common when starting therapy and decline with
time. With regard to DPP-4 inhibitors, there was a small
increase in infection risk including nasopharyngitis (6.4
vs 6.1 %, RR 1.2) and urinary tract infection (3.2 % vs
2.4 %, RR 1.5) [31]. Allergic reactions, although rare,
have been reported [32]. While there was initially con-
cern that incretin-based therapies may be associated
with pancreatitis, multiple retrospective studies and
pooled clinical trial data has failed to find such an asso-
ciation. In large prospective trials of two DPP-4 inhibi-
tors saxagliptin and alogliptin, the risk of acute or
chronic pancreatitis was not increased in diabetic pa-
tients followed up to 2 years when compared to placebo
[33, 34]. Studies examining GLP1-RAs are still ongoing.
Interestingly, baseline data from a cohort of patients in a
study evaluating the GLP1-RA liraglutide found that lip-
ase and amylase levels were above the upper limit of
normal in 16.6 % and 12 % of diabetic patients respect-
ively and often associated with renal dysfunction [35].
Studies that include longer follow-up and stringent clin-
ical definitions to draw definitive conclusions about
incretins and pancreatitis (especially GLP1RAs) are on-
going. With regard to cardiac outcomes, an increased
rate of hospitalization for congestive heart failure has
been linked to saxagliptin [33], however, this has not
been found in other incretin agents. Indeed, animal
models have suggested a cardioprotective effect of incre-
tins in both ischemic heart disease and heart failure that
has not been seen yet in human trials [36]. Again, fur-
ther studies are needed to clarify if these results translate
to major cardiac events, and if so, what subset of pa-
tients is most likely to benefit.
Incretins in the ICU setting
The safety and efficacy of GLP-1 and GLP-1RAs to treat
hyperglycemia have been evaluated in small studies in
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cal and burn. Most of the early studies have evaluated the
cardiovascular benefits of GLP-1 infusion in patients with
recent myocardial infarction or heart failure. These studies
have shown varying degree of improvement in overall clin-
ical outcome in patients with acute myocardial infarction
with decreased left ventricular ejection fraction (LVEF) and
heart failure [37–40]. The focus of this review is the effect
of incretins on glycemia only.
Inpatient use of intravenous GLP-1 without nutrition
Cardiac ICU
An early nonrandomized pilot evaluated the safety and
efficacy of a 72 h GLP-1 infusion in cardiac ICU patients
(n = 21, 50 % with diabetes) with acute myocardial in-
farction and decreased LVEF after a successful primary
angioplasty [37]. The primary outcome was post infusion
LVEF, which improved in all patients in the GLP-1
group. As a minor observation, the authors noted that
mean plasma glucose levels improved in the first 48 h of
the infusion from 162 to 126 mg/dl, and were accom-
panied by a reduction in plasma insulin. When patients
began eating, glucose levels rose only to baseline fasting
levels (168 mg/dl) prior to the infusion, and were associ-
ated with an increase in mean insulin levels from 184 to
301 pmol/L (p < 0.05). Glucose responses were not eval-
uated separately in diabetes patients [37]. Transient nau-
sea was the major side effect noted mostly in patients
without diabetes. In another study of 12 patients with
congestive heart failure (8 with diabetes), five weeks of
GLP-1 infusion improved glycemic control compared to
9 controls (5 with diabetes) as evaluated by an improve-
ment in Hba1c from average 7.7 ± 0.4 to 6.9 ± 0.4 % [38].
It is important to note that cardiac ICU studies have
mainly evaluated LVEF as their primary outcome and
that glucose has not been a major focus of these studies.
Cardiac surgery
Several studies in coronary artery bypass patients have
evaluated GLP-1. In a study of twenty patients undergo-
ing coronary artery bypass graft surgery (CABG), ten pa-
tients (2 with diabetes) were started on a GLP-1 infusion
12 h before surgery and were continued on it periopera-
tively at 1.5pmol/kg/min for 48 h [39]. Compared to the
control group, the GLP-1 group had better preoperative
and intra-operative glucose levels, comparable postoper-
ative glucose levels, and required 45 % less insulin to
achieve a target glucose of 140 mg/dl. The hemodynamic
results were similar and arrhythmias were reduced in
the GLP-1 group. Another study evaluated GLP-1 infu-
sion at 3.6 pmol/kg/min for 12 h after CABG in patients
with insulin naïve type 2 diabetes [40]. Glucose control
was similar in the GLP-1 and insulin groups but insulin
requirements and the frequency of insulin adjustmentswere significantly lower in the GLP-1 group, especially
within the first 6 h.
In a recent study of patients with and without dia-
betes, intraoperative GLP-1 in addition to a standard in-
sulin protocol achieved better glucose control in the
GLP-1 group during the CABG period (p = 0.009) [41].
Post-surgical
Meier et al. evaluated the efficacy of GLP-1 in a trial in-
volving 8 patients with type 2 diabetes treated with oral
hypoglycemic agents undergoing major surgical proce-
dures [42]. 1.2 pmol/kg/min of GLP-1 was infused for
8 h and compared to placebo infused during a separate
8-hour period. Plasma glucose was significantly lower
and reached normal fasting range within 150 min of
GLP-1 infusion compared to persistent hyperglycemia in
the control period (p < 0.001).
A recent study compared 18 post-surgical patients
(9 with diabetes) receiving either intravenous GLP-1 at
1.5 pmol/kg/min or normal saline along with an insulin
infusion for glucose control. GLP-1 along with insulin
reduced the glycemic variability compared to the saline
group and there were no major side effects noted [43].
Inpatient use of GLP-1 with nutrition
Deane et al. evaluated incretins for treatment of hypergly-
cemia associated with enteral nutrition in patients with and
without diabetes [44, 45]. In 7 mechanically ventilated
patients without diabetes GLP-1 infusion at 1.2 pmol/
kg/min was compared to placebo given on a separate
day for hyperglycemia caused by post-pyloric nutri-
tion. Use of GLP-1 significantly attenuated the hyper-
glycemia with peak glucose of 180 mg/dl compared to
216 mg/dl in controls [44]. A similar study was per-
formed in 11 mechanically ventilated diabetes patients
on oral agents before admission. GLP-1 attenuated the
glucose response to <180 mg/dl in over 50 % of pa-
tients versus 36 % of the controls, with mean glucose
of 205 compared to 228 mg/dl in controls [45].
Nauck et al. studied 9 surgical ICU patients (4 with
diabetes) on TPN and 8 healthy controls on intravenous
glucose therapy [46]. GLP-1 was given at 1.2 pmol/kg/
min for 4 hrs. vs placebo for 4 hrs. GLP-1 infusion sig-
nificantly lowered glucose to normoglycemic levels in
healthy control and attenuated hyperglycemia in patients
on total parenteral nutrition (TPN) from peak glucose of
211 to 159 mg/dl; 7 out of 9 patients had blood glucose
less than 150 mg/dl on GLP-1 infusion.
Inpatient use of GLP-1RAs without nutrition
Several trials have evaluated GLP-RA therapy in the ICU
settings. Abuannadi et al. compared 40 patients with hyper-
glycemia (30 with diabetes on oral agents or basal insulin
before admission) who received exenatide infusion to
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get glucose of 90-119 mg/dl (intensive control era-INT)
and 100–140 mg/dl (moderate control era-MOD) [47].
Steady state glucose of 132 mg/dl was reached within 2 h
in the exenatide group compared to 12 h (mean glucose
127 mg/dl) in MOD and 3 h (mean glucose 105 mg/dl) in
the INT group. Mecott et al. evaluated subcutaneous exe-
natide plus insulin therapy in 6 pediatric burn patients and
compared them to 18 controls receiving intensive insulin
therapy. Glucose values and variability were the same in the
two groups, however patient receiving exenatide required
significant less insulin compared to controls [48].
Marso et al. used intravenous exenatide therapy in car-
diac ICU patients and compared it to historical controls
on insulin therapy and found significantly decreased time
to steady state glucose. With exenatide therapy, a glucose
level of 137 mg/dl was reached within 3.9 h compared
to 9.3 h in the recent control group [49]. In another study
conducted on patients undergoing elective CABG, Haluzik
et al. evaluated intravenous exenatide along with insulin.
Adding exenatide improved glucose control without
increasing the incidence of hypoglycemia in these
patients [50].
Summarizing the ICU trials, incretin monotherapy was
most effective in stress hyperglycemia or parenteral and
enteral feeding-induced hyperglycemia in patients with-
out diabetes. In diabetic patients on oral agents with
presumably mild to moderate insulin resistance, glucose
control was successful with incretins alone, but insulin
was required in those with significant insulin resistance.
Here incretin use decreased the cumulative insulin dose,
the frequency of insulin titrations, the time to reach
steady state glucose and glucose variability. Several of
these improvements could potentially improve workflow
and outcomes in hospitalized patients. It is important to
remember, however, that patients with diabetes on large
insulin doses were excluded from these studies.
The most common side effects of GLP-1 in the ICU were
nausea and vomiting, occurring in more than 50 % of the
patients using doses of 1.5 pmol/kg/min or higher. [37, 38].
In newer studies using a lower dose GLP-1 at 1.2 pmol/kg/
min, gastrointestinal side effect were lower. With exenatide
therapy 15–20 % patients had gastrointestinal side effects
[47, 49]. Incretin therapy is known to slow gastric emptying
and may increase the risk of aspiration especially in the
mechanically ventilated ICU patients. Hence, Deane et al.
investigated effect on gastric emptying on 25 mechanically
ventilated patients in the medical ICU. Patients receiving
GLP-1 infusion at 1.2 pmol/kg/min with normal gastric
emptying prior to therapy had significant slowing of their
gastric emptying [51]. However, in patients with known re-
duced gastric emptying there was no further worsening.
Interestingly, only patients with normal gastric emptying
had significant improvement in their glycemia whilepatients with delayed gastric emptying at the start only
showed a trend for reduction in postprandial glycemia.
Hypoglycemia is another major concern with the use of
these agents. 1–2 events of hypoglycemia per 10 patients
were recorded in the early ICU studies using 1.5 pmol/
kg/min of GLP-1 but diminished with dose reduction.
Studies using 1.2 pmol/kg/min did not have any severe
hypoglycemic events [37, 39]. Although exenatide infusion
was associated with varied frequency of hypoglycemia
(0.1–10 %), this was significantly lower than with insu-
lin [41, 47, 49, 50].Incretins in the general wards setting
There is currently little data on the use of incretins in the
inpatient general ward setting. An open-label pilot study
performed by Umpierrez et al. examined the safety and ef-
ficacy of sitagliptin in general medicine and surgery floor
patients [52]. Strict criteria were used to include diabetic
patients treated with diet, oral agents, or insulin at a total
daily dose of less than 0.4 units/kg/day. Patients were ran-
domized to sitagliptin once daily, sitagliptin with basal
insulin, or a traditional basal-bolus regimen. All groups
received correctional scale insulin. Glycemic control
was similar between the groups with no difference in
hypoglycemia or length of hospitalization between the
two groups. The sitagliptin groups required a lower
total daily dose of insulin and fewer insulin injections
compared to those in the traditional basal-bolus group.
Glucose at randomization was a predictor of glucose
control and patients with blood glucose < 180 mg/dl at
randomization had improved blood glucose profile with
treatment.
A larger randomized multicenter trial comparing sita-
gliptin with or without basal insulin to a traditional
basal-bolus regimen is currently ongoing [53]. Further
data is needed to determine the role for incretin-based
therapies in the inpatient settingFuture directions
Schwartz and Defronzo have outlined a process of care to
use incretins on admission and until discharge for patients
with stress hyperglycemia, prediabetes and diabetes, both
on the floor and in the ICU [54]. They suggest starting
these agents prior to, or immediately on an elective admis-
sion, and note this prevents hyperglycemia in majority of
diabetes patients. In the case of persistent hyperglycemia,
insulin was added, initially as a correction scale and then
migrated to basal insulin if necessary. They also suggest
that incretin based therapies be continued until discharge,
when patients could be transitioned back to their home
diabetes regimens. There are no large studies validating
this approach.
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Hyperglycemia management using the current gold stand-
ard of therapy, insulin, improves morbidity in hospitalized
patients. Insulin treatment, although widely used, is labor-
intensive in nature and carries a significant risk of
hypoglycemia. Incretin-based medications as alternative or
additive therapies to insulin in the hospital setting have
shown potential in small pilot ICU and general ward stud-
ies of glucose control. Larger studies using incretin-based
therapies are necessary to establish their safety and effi-
cacy in the hospital setting.
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